title: Beneficial effects of the calcium antagonist isradipine on apolipoproteins in hypertensive patients.
abstract: The objective of the study was to assess the effects of the calcium antagonist isradipine on plasma lipids, lipoproteins, and apolipoproteins in patients with essential hypertension. After a four-week placebo wash-out period, 73 patients (41 men, 32 women) were studied in a double-blind, randomized, crossover study comparing sustained-release isradipine (isradipine SR) with the standard isradipine formulation. Nineteen patients received 5 mg/day and 54 patients 10 mg/day. Lipids were evaluated at the end of the placebo period and after 12 weeks of treatment with isradipine. In both treatment groups, lipid and lipoproteins were not modified. However, apolipoprotein A-I levels increased significantly (P less than .001) and the ratio of apolipoprotein B to apolipoprotein A-I concentration decreased significantly (P less than .01) irrespective of gender. These data show that the levels of plasma apolipoprotein A-I, a strong predictor of coronary heart disease, are favorably affected by isradipine of either formulation. The mechanisms of this effect remain to be elucidated.
authors.affiliation: Unit of Hypertension Research, Le Centre Hospitalier de l'Université Laval, Sainte-Foy, Québec, Canada.
authors.forename: Y
authors.initials: Y
authors.lastname: Lacourcière
authors.forename: C
authors.initials: C
authors.lastname: Gagné
authors.forename: D
authors.initials: D
authors.lastname: Brun
authors.forename: L
authors.initials: L
authors.lastname: Poirier
authors.forename: D
authors.initials: D
authors.lastname: Dion
authors.forename: C
authors.initials: C
authors.lastname: Yardley
mesh_terms: D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood*; D002121:Calcium Channel Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D017275:Isradipine; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D001053:Apolipoproteins; D002121:Calcium Channel Blockers; D008055:Lipids; D008074:Lipoproteins; D011725:Pyridines; D017275:Isradipine